Porous yolk-shell particle Tri-needle coaxial electrospray Pulmonary delivery Ganoderma lucidum polysaccharide Lung oxidative stress A B S T R A C T Chronic lung diseases (e.g. chronic obstructive pulmonary disease and asthma) are associated with oxidative stress and common treatments include various types of inhalation therapies. In this work Ganoderma lucidum polysaccharide (GLP), a naturally occurring antioxidant is loaded into porous Poly (ε-caprolactone) (PCL) particles using a single step tri-needle coaxial electrospray process (Tri-needle CES); with a view to develop therapies to combat oxidative stress. Based on the core-shell structure of porous yolk shell particles (YSPs), GLPloaded YSPs displayed a bi-phasic release pattern. In vitro cell studies indicate GLP-loaded porous YSPs display good biocompatibility and positive attributes towards H 2 O 2 -induced oxidative stress in MRC-5 cells and dramatically attenuate intracellular reactive oxygen species (ROS) levels as well as significantly increase cell viability. In vivo inhalation studies indicate that GLP-loaded porous YSPs can be delivered to deep lung tissue and remain deposited for over 48 h and are subsequently removed by natural clearance mechanisms. Based on current findings GLP-loaded porous YSPs are suitable for pulmonary delivery and display good inhalation therapy potential to treat chronic lung diseases.
Introduction
Chronic lung diseases such as chronic obstructive pulmonary disease (COPD), asthma and chronic bronchitis are a global challenge and as such extensive research in the field has intensified over the last few years (Pelkonen et al., 2017; Xu et al., 2014) . Environmental factors (e.g. air pollution) have played a significant role in the prevalence of such diseases and the latest World Health Organization (WHO) survey indicated that COPD was the third leading cause of death in 2016 (Cosio and Guerassimov, 2012; Organization, 2018; Rabe and Watz, 2017) with approximately 334 million people (4.85% of the world's population) being found to be suffering from asthma in 2010 (Yu et al., 2011) . Many studies have shown these chronic conditions are related to pulmonary oxidative stress (Al-Faqawi et al., 2018; Bernardo et al., 2015) . Oxidative stress reflects the imbalance between the generation of reactive oxygen species (ROS) and the ability to scavenge such harmful substances or repair resulting damage (Burella et al., 2018) . One potential method to overcome this is using antioxidants, such as those classified as Traditional Chinese Medicine (TCM) (e.g. salvia, astragalus polysaccharide, Ganoderma lucidum polysaccharide) (Shang et al., 2018; Veljović et al., 2017; Zhang et al., 2018) . These bioactive compounds have demonstrated appreciable antioxidant effects and have shown to dramatically reduce cell oxidative damage. Ganoderma lucidum polysaccharide (GLP) is an active component of Ganoderma lucidum. Many studies have shown the therapeutic effects of GLP on chronic lung diseases (Liu et al., 2015) due to the compounds' ability to reduce oxidative stress and inflammation while improving cell activity and assisting in recovery from the disease. While these attributes make GLP a suitable candidate for treating specific lung conditions, the effective delivery of GLP to target lung tissue remains a challenge.
The pulmonary route of drug administration has several advantages over enteral and other parenteral routes. Primarily, the pulmonary route provides a larger drug absorption area, greater bioavailability and minimized side effects (Reverchon et al., 2012) . Dry powder inhalers (DPI) are often used for pulmonary particulate administration (Zhou et al., 2014) and the suitability for such devices is driven by drug https://doi.org/10.1016/j.ejps.2018.09.016 Received 30 May 2018; Received in revised form 13 September 2018; Accepted 20 September 2018 powder size, density and porosity (Pinto et al., 2018) .
Large Porous Particles (LPPs) have potential in effective pulmonary delivery due to their unique properties including low density, adaptive aerodynamic diameter, great dispersibility and favorable lung deposition (d 'Angelo et al., 2016) . These physical properties make LPPs more advantageous compared to their small and porous counterparts. For example, larger diameters (e.g. 10 to 20 μm) and lower mass densities (ρ < 0.4 g/cm 3 ) are prone to natural clearance mechanisms found in the lung (e.g. by mucociliary and phagocytosis via macrophages) when compared to particles possessing diameters < 10 μm. LLPs also exhibit greater respiratory fractions when compared to nonporous particles displaying near identical aerodynamic diameters (Gharse and Fiegel, 2016) . Yolk-shell particles (YSPs) are a special class of core-shell particle, where the presence of void spaces within the particles makes them advantageous in several special applications such as biomedical (Hu et al., 2011) , catalysis (Lin et al., 2013) and sensors (Rai et al., 2014) . In biomedical applications, the void space between the shell and core is effective for encapsulation of guest species such as drug molecules which can treat different diseases (Purbia and Paria, 2015) . YSPs also have the multi-stage drug release ability, a characteristic which is often difficult to achieve for naked, core-shell, hollow, and composite particles (Liu et al., 2010) . Thus, it is critical to synthesize LPPs with yolkshell structure for pulmonary delivery while controlling drug release. To date LPPs have been synthesized using a variety of methods which include template-assisted processing (Yamada et al., 2018) , emulsion polymerization (Guan et al., 2016) and reactive sintering (Nayebi et al., 2016) . However, some of these methods require complex intermediate steps, which lead to the loss of material and actives during synthesis, especially where mixing of solvents is involved. In addition, elevated process or synthesis temperatures coupled with undesirable environmental conditions (e.g. pressure) are known to compromise the function of active compounds. Thus, preparation of drug delivery systems at the ambient environment is ideal. In this regard, the electrospraying (ES) technique is suitable, since the process is operational at ambient pressure and temperature and is also low-sheer (Gao et al., 2015) .
An advance in electrospray technologies has involved the use of multiple aligned capillaries during synthesis. Tri-needle coaxial electrospray (Tri-needle CES) is an emerging versatile one-step pharmaceutical engineering process that can be used to prepare micro-and nano-scaled particles possessing complex morphologies . Compared to single or two-needle electrospray (ES) technology, tri-needle CES has emerged as a feasible process to fabricate core-shell microstructures with three co-flowing media using concentrically aligned needle set-ups; ideal for multi-compartment drug delivery dosage form development (Lan et al., 2015) . Particulate surface morphology, internal structure and diameter are controlled through both material properties and process parameters (e.g. polymer concentration, voltage, solution flow rate and collector distance) (Gao et al., 2015) . However, to date studies showing polymeric yolk-shell particles (YSPs, engineered using CES) comprising porous outer shells, solid core and antioxidant active for lung targeting are rare.
In this study, YSPs were fabricated using tri-needle CES technology. Poly (ε-caprolactone) (PCL), a biocompatible polymer approved by FDA (Woo and Arof, 2016) , was utilized as both the porous outer shell and the solid inner core particulate material. The naturally occurring active GLP was loaded into both PCL compartments to achieve biphasic release based on compartment location and morphology. YSP morphology, size, diameter span index, specific surface area (SSA), theoretical mass mean aerodynamic diameter (MMAD t ) and solid state were assessed. In vitro drug release, biocompatibility and antioxidant activity of GLP-loaded porous YSPs was also evaluated. In vivo pulmonary delivery and lung deposition time of YSPs were investigated using an in vivo imaging system.
Materials and methods

Chemicals and materials
Poly (ε-caprolactone) (PCL, Mw = 4.5 × 10 3 g/mol), Ethyl cellulose 
Fabrication of GLP-loaded porous YSPs
GLP-loaded porous YSPs were fabricated using a tri-needle CES setup as shown in Fig. 1a . The device included a tri-needle nozzle system, three precision syringe pumps (KD Scientific, KDS100, USA), jet imaging device (CCD camera) (Baumer TXG02C, Germany), high power voltage supply (Glassman high voltage Inc. series FC, USA) and a ringshaped ground electrode. The tri-needle coaxial nozzle device consisted of three concentrically aligned and enveloped steel needle capillaries. The outer and inner diameter for the outer needle was 2.85 and 2.26 mm, respectively. For the central needle this was 1.60 and 1.07 mm and for the innermost needle this was 0.50 and 0.31 mm, respectively. Formulated liquid was injected into capillaries which was controlled by precision syringe pumps. For all GLP-loaded porous YSPs, formulated media for outer layer consisted of 20 w/v% PCL, 6 w/v% EC dissolved in HAc and GLP powder was dispersion in the liquid. The inner layer consisted of 20 w/v% PCL dissolved in HAc and GLP powder dispersion in the liquid. The formulation flowing through the middle needle was 20 w/v% EC. The flow rates of outer, middle, inner-most formulations were fixed at 5, 1.5, 0.8 ml/h, respectively. An electric field (15 kV) was applied between the tri-axial needle and ground electrode. Anhydrous ethanol was selected as the collector medium to receive atomized YSPs at a deposition distance of 8 cm. All particles were prepared at room temperature (25°C).
Characterization of GLP-loaded porous YSPs
Particle size and morphology
The size and surface morphology of the GLP-loaded porous YSPs was investigated using scanning electron microscopy (SEM, FEI Quanta 650, Utrecht, Netherlands). For SEM analysis, an accelerating voltage of 10 kV was used to obtain micrographs. Samples were dried at 25°C in a desiccator for 24 h. Samples were then fixed on a metallic stub using double-backed conductive tape. Before analysis, all particles were sputter coated (Ion sputter MC 1000, Hitachi, Japan) with gold under vacuum for 90 s using a current intensity of 25 mA. The diameter of GLP-loaded porous YSPs (200 random particles) was analyzed directly from electron micrographs using ImageJ software (National Institutes of Health, USA) and statistical graphs were plotted using Origin software (OriginLab, USA). To assess particle polydispersity, the span index was calculated, which details distribution width (Gavini et al., 2008) , by using Eq. (1):
Here, D 90% , D 10% and D 50% are particle diameters below which 90, 10 and 50% of the cumulative quantities of particles can be found.
For particle cross-section assessment, samples were embedded in a mixture of hardener and epoxy resin. Following solidification, samples were sliced using a stainless steel blade and observed using SEM.
BET specific surface area
The specific surface area (SSA) of GLP-loaded porous YSPs was measured according to BET and BJH isotherm methods (Shi et al., 2012) . For this the adsorption of nitrogen from a liquid nitrogen bath was assessed. GLP-loaded porous YSPs were degassed for 2 h at 30°C to remove all absorbed gas and volatile substances. The SSA of particles was measured using the BET multi-point method.
The theoretical mass mean aerodynamic diameter (MMAD t )
The theoretical mass mean diameter (MMAD t ) of GLP-loaded porous YSPs was calculated based on tapped density. Briefly, 100 mg of GLPloaded porous YSPs were placed in a purpose-made 10 ml ( ± 0.05 ml) graduated cylinder. The cylinder was then tapped 1000 times until a consistent height (volume plateau) was achieved and the final volume (ml) was recorded. Tapped density was calculated using Eq. (2) 
MMAD t was calculated according to the following Eq. (3):
Here, d is the geometric mean diameter; ρ is the mass mean density of the particles, which is tapped density here; ρ 0 is a reference density (1 g/ml) and χ is the dynamic shape factor, which is 1 for a sphere (Razavi Rohani et al., 2014) .
FTIR spectroscopy
Fourier transform infrared spectroscopy (FTIR) was utilized to determine composition and chemical structure of GLP-loaded porous YSPs. For sample preparation, the KBr pellet pressing method was used (Yao et al., 2016) . Here, 2 mg of sample was mixed with 200 mg KBr medium and grinded in a mortar. The mixture was compressed into transparent pellets under a pressure of 12 MPa. Once prepared, FTIR (IR Affinity 1, Shimadzu, Japan) was used to scan pellets, and spectra were recorded in the range of 4500 to 400 cm
. Spectra were obtained using 30 scans at a resolution of 4 cm −1 .
2.3.5. X-ray powder diffraction X-ray power diffraction was used to analyze the physical form of GLP in porous YSPs. Spectra were recorded with a 5005 Bruker-AXS diffractometer (Zeiss, Oberkochen, Germany), operating at 40 mA and 40 kV. The scanning rate was 0.35 s/step. Spectra were collected in 2θ from 10°to 90°.
GLP loading and in vitro release study
The loading capacity (LC) and encapsulation efficiency (EE) of GLP in GLP-loaded porous YSPs were determined using the following equations (Chatterjee and Judeh, 2015; Moomand and Lim, 2014) . The LC of GLP in the porous YSPs was calculated using Eq. (4):
The EE of GLP in the porous YSPs was calculated using Eq. (5):
To evaluate drug release in vitro, 100 mg of GLP-loaded porous YSPs were dispersed in 10 ml release medium (PBS, pH = 7.4) and mechanically stirred at 37°C. As shown in Fig. S1 the most characteristic UV absorption of GLP was determined to be at 304 nm (UV-2600 spectrophotometer, Shimadzu, Japan). The linear standard curve at this wavelength was obtained from GLP solutions as shown in Fig. S2 . At pre-determined time intervals, 2 ml of GLP release solution was transferred for UV absorption measurements after centrifugation at 1500 rpm for 1 min and this was replaced with 2 ml of fresh test medium. The percentage of GLP released was calculated using Eq. (6): 
Here, Q t is the quantity of GLP released at time t, Q s is the total quantity released.
2.5. In vitro cell studies 2.5.1. Cell culture Human lung fibroblast MRC-5 cell lines were obtained from American Type Culture Collection (ATCC) and cultured in MEM medium containing 10 v/v% fetal bovine serum (FBS) and 1 v/v% penicillin/streptomycin. The cells were maintained at 37°C in a humidified incubator with 5% CO 2 .
Cell morphology detection
MRC-5 cells were seeded into 24-well plates at a density of 6 × 10 4 per well and were allowed to adhere for 24 h (sterile glass coverslips were placed at the base of each well). Subsequently, cells were treated with 400 μmol/l H 2 O 2 for 4 h. Various quantities of GLP-loaded porous YSPs (0.3, 1 and 3 mg/ml) were then added to cells and incubated for 48 h. The culture medium was removed and each well was rinsed with PBS three times before experiments. Cells were then fixed in 4% PFA for 15 min. Cell membranes were permeabilized with 0.1% Triton X-100 for 10 min. Cell cytoskeleton and nuclei were stained with TRITC phalloidin and DAPI for 20 and 15 min, respectively. Glass coverslips were localized using mounting medium, and detected using an inverted fluorescence microscope (Nikon, Ti-S, Japan). Staining and dye inclusion procedures were based on previous studies (Li et al., 2014) .
Cell viability
Cell viability was evaluated by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay. MRC-5 cells were seeded into 96-well plates at a density of 10,000 cells/well/0.1 ml MEM cultured medium. Cells were incubated overnight. Cells were treated with 400 μmol/l H 2 O 2 for 4 h. Various quantities of GLP-loaded porous YSPs (0.3, 1 and 3 mg/ml) were then added to cells and incubated for 48 h. Or cells was treated with various quantities of GLP-loaded porous YSPs (0.3, 1 and 3 mg/ml) only for 24 h or 48 h. The culture medium was removed and cells were washed with PBS and then incubated with culture medium containing MTT (0.25 mg/ml) at 37°C for 4 h. Washed cells and 100 μl of DMSO were added to dissolve crystals formed by living cells. The absorbance of each well was measured using a micro-plate reader (VersaMax, Molecular Devices, USA) at a wavelength of 570 nm . Cell viability was calculated using Eq. (7).
where Ab. means the absorbance.
2.5.4. Live/dead assay MRC-5 cells were seeded into 6-well plates at a density of 3 × 10 5 per well and allowed to adhere for 24 h. The culture medium was removed and serum-free medium with 400 μmol/l H 2 O 2 was added into the well for 4 h. The cells were then rinsed three times with PBS. Serumfree medium containing various quantities of GLP-loaded porous YSPs (0.3, 1 and 3 mg/ml) was then added and the cells were incubated for 48 h. To distinguish between live and dead cells; Calcein-AM and propidium iodide (PI) were used for staining and the cells were assessed using an inverted fluorescence microscope (Nikon, Ti-S, Japan). In order to determine the ratio of living to dead cells, calcein fluorescence intensity was analyzed using ImageJ software.
2.5.5. ROS staining ROS staining was performed using a ROS staining kit. MRC-5 cells were seeded into 6-well plates at a density of 3 × 10 5 per well and allowed to adhere for 24 h. The cells were treated with 400 μmol/l H 2 O 2 for 4 h, and were treated with known quantities (0.3, 1 and 3 mg/ ml) of GLP-loaded porous YSPs for 48 h. Cells were then washed three times in PBS and incubated in 15 μM DCFH-DA at 37°C for 30 min. Stained cells were then observed using an inverted fluorescence microscope (Nikon, Ti-S, Japan). To quantify ROS levels DCFH fluorescence intensity was analyzed using ImageJ software.
In vivo inhalation study
Male specific pathogen-free (SPF) KunMing mice were procured from SLAC Laboratory, Shanghai. All animal studies were performed in accordance with guidelines for the care and use of laboratory animals under a protocol approved by Zhejiang University Animal Research Committee.
Prior to testing, KunMing mice (6-8 weeks old, 18-20 g) were anesthetized with isoflurane and had hair removed (n = 6). Fluorescence detection was performed on mice (at 0 h) prior to pulmonary delivery of particles. Then, GLP-loaded porous YSPs stained with Sudan Red G were insufflated into the lungs of anesthetized mice using a dry powder insufflator device (Dry Powder Insufflator™, DP-4-R), a laryngoscope (Penn-Century, Philadelphia, PA) and a disposable 1.0 ml air syringe to deliver directly into mice lungs. At pre-determined time intervals (1, 3, 6, 12, 24 and 48 h), mice were anesthetized with isoflurane and fluorescence detection was performed on lung tissue (in vivo). To confirm lung delivery, one subject was used to detect immediate fluorescence location following pulmonary delivery (Fig. S3a) of GLP-loaded porous YSPs. Here, the test specimen was executed by cervical dislocation and the chest region was subsequently excised to access and enable whole lung removal, fluorescence within lung tissue is shown in Fig. S3b . In all cases fluorescence was detected using an in vivo imaging system (Imaging System IVIS Lumina Series III, Caliper Life Sciences, PerkinElmer). Fluorescent intensity was analyzed by IVIS Lumina III Software (Caliper Life Sciences, PerkinElmer).
Statistical analysis
All experiments were performed independently and repeated at least three times. Data is presented as mean ± standard deviation. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Tukey's HSD post hoc comparison. Statistical analysis was carried out using SPSS software (SPSS Statistics v21, IBM, UK). P < 0.05 was considered to have statistical significance.
Results and discussion
Fabrication of GLP-loaded porous YSPs
GLP-loaded porous YSPs were successfully prepared using tri-needle CES technology. A schematic diagram of the method is shown in Fig. 1a . Fig. 1b shows formulations yielding the dripping mode once infused into tri-needle nozzle assembly at 0 kV. This mode results due to syringe pump infusion action and gravitational force. In contrast, at 15 kV stable-jetting behavior is obtained as shown in Fig. 1c. 
Particle characterization
GLP-loaded porous YSP surface morphology was observed using SEM. The resulting particles were spherical with a porous shell, as shown in Fig. 2a . A cross-section electron micrograph of GLP-loaded porous YSPs is shown in Fig. 2b , confirming the anticipated yolk-shell structure (particle in particle) as well as void space (central EC layer dissolves in ethanol) between porous shell and solid core regions. Fig. 2c shows GLP-loaded porous YSP diameter size distribution and the mean were found to be 13.37 ± 0.20 μm with a diameter span index of 0.50 μm. These results indicate stable and near uniform particle engineering. Many studies indicate large porous microparticles are well suited for long-term treatment as inhalation based therapies. It has been established that microparticle porosity decreases the aerodynamic density to suffice aerosolization. Specifically, porous microparticles with a MMAD of 1-5 μm can be delivered to deep lung tissue (d 'Angelo et al., 2016) .
Here, mass mean density of GLP-loaded porous YSPs was 0.122 ± 0.013 g/cm 3 and MMAD t was 4.66 ± 0.25 μm; indicating that GLP-loaded porous YSPs are suitable for pulmonary delivery deep lung targeting. In fact, widespread deposition along bronchi and bronchioles is also expected on the basis of previous studies on rat lung using similar LPPs possessing MMAD < 10 μm. Preliminary estimation of MMAD t is indicative of GLP-loaded porous YSPs to possess good flow properties and aerodynamic behavior (Ungaro et al., 2010) . The extent of lung deposition can be controlled or optimized through further formulation design and enhancement.
Further pore analysis of GLP-loaded porous YSPs was performed using BET. Results show that SSA of GLP-loaded porous YSPs was 8.6359 m 2 /g. Particle pore volume and diameter were 0.0537 ml/g and 16.01 nm, respectively. N 2 adsorption-desorption isotherms are shown in Fig. 2d . According to IUPAC, isotherms for GLP-loaded porous YSPs are characteristic of type III, suggesting weak interaction between particles and N 2 under low pressure, which further eludes to their porous nature . Here, YSPs possess a large SSA due to their porous architecture and void space. In this regard increased contact area between particles and lung tissue may facilitate burst release of the active component.
FTIR spectroscopy was used to confirm particle chemical composition and stability Fig. 2e shows infrared Here, characteristic peaks of GLP were not clearly observed for GLPloaded porous YSPs. This is due to the relative low GLP content loaded in particle shells when compared to other polymeric constituents. Furthermore, overlapping peaks arising from other constituents may conceal absorption peaks of GLP. Results also reveal no chemical interaction between GLP and PCL, which is in agreement with previous reports (Wu, 2014; Yao et al., 2018) . Solid state characteristics of GLP in porous YSPs were characterized using XRD. As shown in Fig. 2f , characteristic peaks in XRD patterns indicate that PCL is present in crystalline form (Dhanka et al., 2017) . GLP diffraction patterns exhibit diffuse halos elucidating amorphous format. GLP-loaded porous YSPs show characteristic peaks instead of diffuse halos, suggesting GLP had been successfully encapsulated (Ni et al., 2017) .
In vitro release study
Core-loaded YSPs (hosting GLP only in particle core), shell-loaded YSPs (hosting GLP only in particle shell) and GLP-loaded porous YSPs (GLP loading into both core and shell of particles) were used to evaluate in vitro drug release process based on structural variations. Tri-needle CES is an effective way to load bioactive components into micrometer or nanometer scaled particles in a single-step. LC provides an indication on GLP encapsulation process feasibility into porous YSPs, while EE confirms GLP encapsulation levels within particles. LCs and EEs of coreloaded YSPs, shell-loaded YSPs and GLP-loaded porous YSPs were 0.41 ± 0.01, 1.84 ± 0.05, 2.22 ± 0.07% and 92.7 ± 1.5, 89.5 ± 2.5, 92.0 ± 2.7%, respectively. The results suggest that YSPs fabricated via tri-needle CES technology can successfully load GLP into YSPs; which in turn display appreciable stability and high quantities of GLP encapsulation. Fig. 3a shows a schematic diagram elucidating the biphasic release nature of YSPs. In vitro release profiles over an 8 h test period is shown in Fig. 3b (different particle schematics shown as insets). The porous structure of shell-loaded YSPs significantly increases the contact area between particles and release medium. In addition, the high water solubility of GLP leads to a high level of burst release (98.1% of contained drug) from shell-loaded YSPs in the first 30 min. Coreloaded YSPs, which host GLP only in the core, exhibit sustained release over 4 h (89.5% of contained drug). GLP-loaded porous YSPs display a biphasic release pattern; which includes a burst release period during the first 30 min (70.4% of contained drug) and a sustained release phase from 30 min to 4 h (96.2% of contained drug). Sustained release was studied for a further 7 days and the release profiles are shown in Fig. 3c (release between 0 and 2 h shown as insets). Core-loaded YSPs, shell-loaded YSPs and GLP-loaded porous YSPs released 93.8, 99.9 and 96.7% of encapsulated drug, respectively, over the extended test period.
Burst release from YSPs is facilitated by the porous structure because of increased contact area between particles and release medium. This porous structure exhibits a large SSA and this can be regulated by varying the contents of infused materials during the electrospraying process. Biphasic release profile from YSPs suggest the delivery system is capable of delivering rapid and sustained release of active. Thus, GLP-loaded porous YSPs (which possess a porous shell and solid core) can provide rapid onset and long-lasting treatment strategies; where YSP shell provides rapid release and the core provides a more sustained release. These findings were in agreement with previous reports (Han and Steckl, 2013; Sohier et al., 2006) . Although results from this in vitro release model are under sink conditions, in vivo release behavior from GLP-loaded porous YSPs will provide valuable complimentary information.
Biocompatibility evaluation of GLP-loaded porous YSPs
Although the GLP-loaded porous YSPs were engineered from FDA approved materials (PCL), particles may still pose potential toxic effects due to residual solvent. To investigate particulate biocompatibility, MRC-5 cells were incubated and maintained in MEM medium containing 10 v/v% fetal bovine serum (FBS) and 1 v/v% penicillin/ streptomycin at 37°C, in 5% CO 2 . The culture medium was changed every 24 h. GLP-loaded porous YSPs were sterilized using UV light. Cells were treated with various concentrations of YSPs (0.3, 1, 3 mg/ ml) and assessed post 48 h incubation period. Cell nuclei were stained with DAPI (blue) and their cytoskeleton were stained with TRITC phalloidin (red). Representative images are shown in Fig. 4a , and were compared to control group. Addition of 0.3, 1 or 3 mg/ml GLP-loaded porous YSPs did not cause any morphological change to MRC-5 cells. Cells retained their fusiform shape with the nucleus displayed clearly, similar to the control group. This shows good biocompatibility of GLPloaded porous YSPs (Cui et al., 2018) .
Cell viability was evaluated further using MTT assay. Cytotoxicity of particles was reflected through cell viability. By comparing various particle concentration test groups (0.3, 1 and 3 mg/ml) to the control (blank), cell viability histograms were established as shown in Fig. 4b . Viability is normalized as the relative percentage with respect to the control group. Cell viability of the control group was 100% and no significant difference was found between this and test samples at 24 and 48 h incubation times. This indicates all GLP-loaded porous YSPs exhibited negligible cytotoxicity towards MRC-5 cells. These findings were consistent with previous reports (Yao et al., 2018; Zelenková et al., 2018) .
Therapeutic effect evaluation of GLP-loaded porous YSPs
GLP is a very common TCM but modern pharmaceutical research shows that GLP has strong physiological and health benefits, including antioxidant activities. Previous studies report that GLP is capable of significantly increasing cell viability under H 2 O 2 -induced oxidative stress and reduce ROS formation . Thus, a H 2 O 2 -induced cell oxidative stress model was used to validate therapeutic effects of GLP-loaded porous YSPs in this study (Fig. 5) . As shown in Fig. 5a , cell morphology was evaluated using Phalloidin/DAPI staining following cell damage in H 2 O 2 . When compared to the control group, cell morphology of H 2 O 2 treated groups (0.3, 1 or 3 mg/ml GLP-loaded porous YSPs) appear different; with cell shrinkage and clustering the most common features eluding to damage (Hsin-Ling et al., 2017 ). However, for particle treated groups, cell damage recovery is apparent and is dose-dependent; higher YSP concentrations exhibited better cellular morphology restoration.
Live/dead assays were used to further study the therapeutic effect of GLP-loaded porous YSPs on H 2 O 2 -induced oxidative damage. Representative images of live/dead assays are shown in Fig. 5b .
Incubation of MRC-5 cells with H 2 O 2 results in a dramatic reduction of living cells (stained with Calcein-AM, green) and a significant increase in dead cells (stained with PI, red). As shown previously, the number of living cells is dose-dependent and increases with GLP-loaded porous YSP concentration in culture. Quantitative analysis of calcein fluorescence intensity is shown in Fig. 5d . Compared to the control group (non H 2 O 2 treated), the fluorescence intensity of H 2 O 2 groups (alone) decreases dramatically; confirming that H 2 O 2 significantly reduces the number of viable cells. Fluorescence intensity for 0.3 mg/ml YSP treated group increases, but not significantly when compared to the H 2 O 2 (alone) group. Intensities for 1 and 3 mg/ml YSPs groups increased significantly. Results of live/dead assay indicate that GLPloaded porous YSPs significantly increase cell viability following H 2 O 2 damage to cells and restore cellular health. The effect of GLP-loaded porous YSPs against cellular oxidative stress is most likely to be related to GLP scavenging ability of intracellular ROS. Cellular oxidative damage is a well-established mechanism leading to cell injury. ROS binds with most normal cellular components; reacting with unsaturated bonds of membrane lipid, denaturing proteins and attacking nucleic acids (Fojta et al., 2016) . To further investigate whether GLP-loaded porous YSPs improved cell viability, the particle scavenging ability of intracellular ROS was investigated. ROS staining was used to investigate ROS levels following treatment with different concentrations of GLP-loaded porous YSPs. Representative images are shown in Fig. 5c . Intracellular ROS levels show a dramatic increase for H 2 O 2 treated groups, although as observed previously, cell recovery through addition of GLP-loaded porous YSPs (0.3, 1, 3 mg/ml) is dose-dependent. The results for DCFA fluorescence intensity analysis are shown in Fig. 5e . The fluorescence intensity of H 2 O 2 treated groups is increased significantly; confirming that H 2 O 2 damage increases intracellular ROS levels. Fluorescence intensity for the 0.3 mg/ml YSP treated group is reduced, but not significantly when compared to the H 2 O 2 (alone) group. The intensity for 1 and 3 mg/ml YSPs groups were significantly reduced which again eludes to the dose dependent nature to combat cellular damage. The results suggest ROS is effectively scavenged by GLP from GLP-loaded porous YSPs. This may be the key driving factor for GLP-loaded porous YSPs increasing the quantity of living cells following H 2 O 2 injury.
MTT assay was used to further evaluate biocompatibility of GLPloaded porous YSPs. The results are shown in Fig. 5e . Incubation of MRC-5 cells with concentration of 400 μmol/l H 2 O 2 for 4 h resulted in a 52.19 ± 3.15% decrease in cell viability. Cells were initially damaged with H 2 O 2 and subsequently treated with 0.3, 1 and 3 mg/ml GLPloaded porous YSPs. Cell viability increased up to 60.30 ± 2.26%, 73.17 ± 4.05%, 80.11 ± 2.58% in dose-dependent manner. Cell viability for 1 and 3 mg/ml groups increased and this was statistically significant.
Cells incubated with 400 μmol/l H 2 O 2 for 4 h display altered morphology, decreased cell viability and increased intracellular ROS levels. In contrast, GLP released from GLP-loaded porous YSPs increase cell viability through scavenging intracellular ROS, reduce H 2 O 2 -induced oxidative stress and have significant therapeutic effect on H 2 O 2 -induced cellular damage. These results are consistent with previous studies (Sun et al., 2017) .
In vivo inhalation study
In vitro assessment indicates YSPs developed in this study have potential applications in treating several lung diseases. Administration of drug through inhalation based therapies has clear advantages over other enteral and parenteral routes (e.g. solid oral dosage forms and intravenous injections (Loira-Pastoriza et al., 2014) . GLP-loaded porous YSP suitability as a pulmonary delivery system was further assessed. GLP-loaded porous YSPs were loaded with red fluorescence and fluorescence localization, particle bio-distribution and deposition time in mice lung were observed through in vivo imaging. GLP-loaded porous YSPs were delivered to mice lungs using a dry powder insufflator device and a disposable 1.0 ml air syringe. 2 mg of YSP samples were loaded into the device and ejected with 0.5 ml air. Following lung administration, the device was checked for any particulate residue. The results shown in Fig. 6a , show red fluorescence was observed in the lung of mice following pulmonary delivery at 1, 3, 6, 12, 24, 48 h time intervals. In addition, fluorescent intensity was quantified, and the results are shown in Fig. 6b . The fluorescent signal at the 1 h test group is strong and gradually weakens over time. Fluorescence intensity of particles appears very weak at 48 h, confirming that most particles were removed from the lungs via natural clearance mechanisms. This observation is also consistent with previous studies (Ni et al., 2017) .
Many studies show that large particles (MMAD > 5 μm) are filtered in the upper airways (mouth, trachea and main bronchi) through inertial impaction. Particles with MMAD between 0.1 and 1 μm are mostly exhaled. Particles possessing MMAD values between 1 and 5 μm generally deposit by gravitational forces, settling in the central and distal tracts. Particles in this "respirable" range flow more easily with the inhalation air stream and can navigate the twists and turns of the complex lung airways (Gharse and Fiegel, 2016) . Here, GLP-loaded porous YSPs, by virtue of their large size (13.26 ± 2.90 μm) and suitable MMAD t (4.66 ± 0.25 μm) are well suited for deep lung delivery (Fig. S3b) . Furthermore, these particles are retained in the lungs for a long time (over 48 h) and are gradually cleared through natural mechanisms. These results indicate that GLP-loaded porous YSPs are suitable for pulmonary drug delivery.
Conclusions
In summary, GLP-loaded porous YSPs were successfully fabricated using tri-needle CES technology. The surface morphology and interior structure of GLP-loaded porous YSPs was demonstrated using SEM. Mean diameter, SSA, pore volume and pore diameter also confirmed key morphological features. FTIR and XRD analysis indicate successful and stable encapsulation of GLP within porous YSPs. In vitro drug release studies showed that GLP-loaded porous YSPs displayed biphasic release characteristics (i.e., both burst and sustained release). Particle biocompatibility was also confirmed using various in vitro assays. GLPloaded porous YSPs were also found to have suitable MMAD t , which is critical for pulmonary delivery. Particle bio-distribution (mouse model) and lung deposition time was confirmed using in vivo imaging. In summary, GLP-loaded porous YSPs display promising attributes as a potential treatment for chronic pulmonary diseases.
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